Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.10
AVEO's Cash to Debt is ranked higher than
63% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. AVEO: 3.10 )
AVEO' s 10-Year Cash to Debt Range
Min: 1.54   Max: No Debt
Current: 3.1

Equity to Asset 0.40
AVEO's Equity to Asset is ranked higher than
58% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AVEO: 0.40 )
AVEO' s 10-Year Equity to Asset Range
Min: -3.21   Max: 0.79
Current: 0.4

-3.21
0.79
F-Score: 3
Z-Score: -8.52
M-Score: -4.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -291.99
AVEO's Operating margin (%) is ranked higher than
64% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. AVEO: -291.99 )
AVEO' s 10-Year Operating margin (%) Range
Min: -8035.89   Max: 20.59
Current: -291.99

-8035.89
20.59
Net-margin (%) -303.15
AVEO's Net-margin (%) is ranked higher than
64% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. AVEO: -303.15 )
AVEO' s 10-Year Net-margin (%) Range
Min: -8277.57   Max: 18.59
Current: -303.15

-8277.57
18.59
ROE (%) -92.23
AVEO's ROE (%) is ranked higher than
60% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. AVEO: -92.23 )
AVEO' s 10-Year ROE (%) Range
Min: -197.14   Max: 20.76
Current: -92.23

-197.14
20.76
ROA (%) -44.26
AVEO's ROA (%) is ranked higher than
66% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. AVEO: -44.26 )
AVEO' s 10-Year ROA (%) Range
Min: -88.25   Max: 13.74
Current: -44.26

-88.25
13.74
ROC (Joel Greenblatt) (%) -350.00
AVEO's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. AVEO: -350.00 )
AVEO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1669.78   Max: 678.74
Current: -350

-1669.78
678.74
Revenue Growth (%) -74.20
AVEO's Revenue Growth (%) is ranked higher than
57% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. AVEO: -74.20 )
AVEO' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -67.6
Current: -74.2

EBITDA Growth (%) -2.30
AVEO's EBITDA Growth (%) is ranked higher than
78% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. AVEO: -2.30 )
AVEO' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -2.3
Current: -2.3

EPS Growth (%) -3.00
AVEO's EPS Growth (%) is ranked higher than
79% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. AVEO: -3.00 )
AVEO' s 10-Year EPS Growth (%) Range
Min: 0   Max: -3
Current: -3

» AVEO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AVEO Guru Trades in Q4 2013

Paul Tudor Jones 109,101 sh (New)
Chuck Royce 218,583 sh (+36.61%)
Seth Klarman 3,829,350 sh (unchged)
Jim Simons 1,299,070 sh (-0.74%)
» More
Q1 2014

AVEO Guru Trades in Q1 2014

Steven Cohen 500,000 sh (New)
Seth Klarman 3,829,350 sh (unchged)
Chuck Royce Sold Out
Jim Simons 1,275,453 sh (-1.82%)
Paul Tudor Jones 106,701 sh (-2.2%)
» More
Q2 2014

AVEO Guru Trades in Q2 2014

George Soros 49,076 sh (New)
Jim Simons 1,343,488 sh (+5.33%)
Paul Tudor Jones 106,701 sh (unchged)
Seth Klarman 3,829,350 sh (unchged)
» More
Q3 2014

AVEO Guru Trades in Q3 2014

Seth Klarman 3,829,350 sh (unchged)
George Soros Sold Out
Paul Tudor Jones 99,319 sh (-6.92%)
Jim Simons 591,700 sh (-55.96%)
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Sold Out $1.09 - $1.79 $ 0.81-36%0
George Soros 2014-06-30 New Buy$1.02 - $1.72 $ 0.81-37%49076
Seth Klarman 2013-06-30 Reduce -21.9%0.26%$2.34 - $8.27 $ 0.81-81%3829350
George Soros 2011-12-31 Sold Out 0.0031%$14.53 - $17.35 $ 0.81-90%0
Seth Klarman 2011-09-30 Add 12.79%0.29%$15.12 - $20.77 $ 0.81-95%5000000
George Soros 2011-09-30 Reduce -92.8%0.04%$15.12 - $20.77 $ 0.81-95%11600
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.10
AVEO's P/B is ranked higher than
98% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. AVEO: 1.10 )
AVEO' s 10-Year P/B Range
Min: 0.87   Max: 22.16
Current: 1.1

0.87
22.16
P/S 1.90
AVEO's P/S is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. AVEO: 1.90 )
AVEO' s 10-Year P/S Range
Min: 0.64   Max: 111.5
Current: 1.9

0.64
111.5
EV-to-EBIT 0.11
AVEO's EV-to-EBIT is ranked higher than
100% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AVEO: 0.11 )
AVEO' s 10-Year EV-to-EBIT Range
Min: -8.1   Max: 16.9
Current: 0.11

-8.1
16.9
Current Ratio 1.84
AVEO's Current Ratio is ranked higher than
59% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. AVEO: 1.84 )
AVEO' s 10-Year Current Ratio Range
Min: 1.55   Max: 9.47
Current: 1.84

1.55
9.47
Quick Ratio 1.84
AVEO's Quick Ratio is ranked higher than
61% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. AVEO: 1.84 )
AVEO' s 10-Year Quick Ratio Range
Min: 1.55   Max: 9.47
Current: 1.84

1.55
9.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.23
AVEO's Price/Net Cash is ranked higher than
94% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. AVEO: 3.23 )
AVEO' s 10-Year Price/Net Cash Range
Min: 1.75   Max: 24.76
Current: 3.23

1.75
24.76
Price/Net Current Asset Value 2.96
AVEO's Price/Net Current Asset Value is ranked higher than
95% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. AVEO: 2.96 )
AVEO' s 10-Year Price/Net Current Asset Value Range
Min: 1.62   Max: 24.22
Current: 2.96

1.62
24.22
Price/Tangible Book 1.08
AVEO's Price/Tangible Book is ranked higher than
99% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. AVEO: 1.08 )
AVEO' s 10-Year Price/Tangible Book Range
Min: 1.2   Max: 14.66
Current: 1.08

1.2
14.66
Price/Median PS Value 0.44
AVEO's Price/Median PS Value is ranked higher than
95% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. AVEO: 0.44 )
AVEO' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 23.66
Current: 0.44

0.17
23.66
Earnings Yield (Greenblatt) 909.10
AVEO's Earnings Yield (Greenblatt) is ranked higher than
100% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. AVEO: 909.10 )
AVEO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.9   Max: 48134.7
Current: 909.1

5.9
48134.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:VPA.Germany,
AVEO Pharmaceuticals Inc was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The Company is a cancer therapeutics company that discovers, develops and commercializes targeted cancer therapies to impact patients' lives. The Company's proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. Its product under development include: AV-203, an anti-ErbB3 monoclonal antibody with broad therapeutic potential. Ficlatuzumab, is a Hepatocyte Growth Factor, or HGF, inhibitory antibody. Tivozanib, is an investigational tyrosine kinase inhibitor of all three vascular endothelial growth factor, or VEGF receptors. AV-380, a potential first-in-class GDF-15 inhibitor, was discovered using proprietary Human Response Platform, that provides the company unique insights into cancer and related disease biology. The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc. and GlaxoSmithKline plc. The Company contracts with third parties for the manufacture of clinical product candidates. On March 9, 2014, Company entered into a manufacturing agreement with AbbVie Inc. for the process and development of AV-380. In August 2010, it entered into an agreement with Gallus BioPharmaceuticals, LLC for the clinical manufacture of AV-203 drug substance. The Company seeks trademark protection in the U.S. and foreign jurisdictions where available and when appropriate.
» More Articles for AVEO

Headlines

Articles On GuruFocus.com
Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
comment on AVEO Mar 15 2013 
comment on AVEO Mar 15 2013 
Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

More From Other Websites
AVEO PHARMACEUTICALS INC Financials Nov 18 2014
AVEO Gains on Tivozanib Agreement with Ophthotech Nov 13 2014
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 12 2014
AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF... Nov 11 2014
AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF... Nov 11 2014
10-Q for AVEO Pharmaceuticals, Inc. Nov 07 2014
AVEO Oncology Reports Third Quarter 2014 Financial Results Nov 05 2014
AVEO Oncology Reports Third Quarter 2014 Financial Results Nov 05 2014
Will AVEO Pharmaceuticals (AVEO) Surprise this Earnings? Nov 05 2014
AVEO PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 05 2014
Leon Cooperman To Cash In On Atlas Energy Acquisition Oct 13 2014
AVEO-Biodesix Reveal Lung Cancer Study Exploratory Data Oct 02 2014
BioMed Leases Space to Baxter for R&D Center in MA Sep 30 2014
AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced... Sep 29 2014
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell... Sep 29 2014
AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference Sep 26 2014
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination... Sep 26 2014
AVEO Oncology Announces Lease Termination and Amendment to Debt Financing Facility Sep 26 2014
Clinical Data on AVEO Oncology’s Ficlatuzumab and Tivozanib to Be Presented at the ESMO 2014... Sep 17 2014
AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue? Aug 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK